Belgiophar SRL
Belgiophar reported revenue of 152,095 € for the 2025 financial year (annual accounts filed with the NBB on 08 Sep 2026).
The score of Belgiophar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue -45 % Total assets -63 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Belgiophar's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 152,095 € | ||||
| Net result | −28,157 € | ||||
| Equity | −124,272 € | ||||
| Cash | 33,865 € | ||||
| EBITDA | −108,270 € | ||||
| Total assets | 106,855 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 08 Sep 2026
- Year ended 31 Dec 2024filed on 28 Sep 2025
- Year ended 31 Dec 2023filed on 31 Aug 2024
- Year ended 31 Dec 2022filed on 13 Oct 2023
- Year ended 31 Dec 2021filed on 06 Jan 2023
Belgiophar's financial analysis
- Solvency-116.3%sector median: 26.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Belgiophar
Belgiophar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0760.405.269
- VAT number
- BE0760405269
- Peppol
- Registered · 0208:0760405269 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 22 Dec 2020
- Registered office
- 1070 Anderlecht
- Latest accounts
- 2025 · filed on 08 Sep 2026
- Activity
- Wholesale of other food n.e.c. (NACE 46389)
Belgiophar (SRL) has been based in Anderlecht since 2020, active in: wholesale of other food n.e.c.. For 2025, it reports revenue of 152,095 €, a net loss of 28,157 € and equity of −124,272 €. Its solvency stands at -116.3%, below the median of its sector (26.7%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Belgiophar
Companies in the same business, of comparable size and area, outside its group.
- Brupharm Pharmalab Manufacture of pharmaceutical preparations Mons · balance sheet 298,430 €
- Comed Manufacture of pharmaceutical preparations Bilzen-Hoeselt · balance sheet €1.34m
- Deba Pharma Manufacture of pharmaceutical preparations Kortrijk · balance sheet €6.57m
- Laboratoires Forte Pharma Benelux Wholesale of other food Brussels · balance sheet €1.85m
- Nutraphar BE Manufacture of pharmaceutical preparations Lasne · balance sheet 1,779 €
- Advanced Practical Diagnostics Manufacture of pharmaceutical preparations Turnhout · balance sheet €4.50m
- Linden API Wholesale of pharmaceutical and medical goods Ixelles · balance sheet 12,520 €
- Liwaes Wholesale of pharmaceutical and medical goods Roosdaal · balance sheet 98,407 €
Frequently asked questions about Belgiophar
What is the revenue of Belgiophar?
According to the 2025 annual accounts filed with the NBB, the revenue of Belgiophar amounts to 152,095 €.
What is the VAT number of Belgiophar?
In Belgium, the VAT number is the company number prefixed with BE: BE0760405269 for Belgiophar, if the company is VAT-registered. Its company number (CBE) is 0760.405.269.
Where is the registered office of Belgiophar?
According to the CBE register, the registered office of Belgiophar is in 1070 Anderlecht.
What is the equity of Belgiophar?
At the close of the 2025 financial year, the equity of Belgiophar amounts to -124,272 €, a solvency of -116.3% of total assets.
Who manages Belgiophar?
The register lists 1 active mandates at Belgiophar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Belgiophar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →